Ascentage Pharma
亚盛医药
Executive Summary
Ascentage Pharma is a Suzhou-based biotech focused on apoptosis-targeted therapies with validated deal-making capability, evidenced by their successful Takeda partnership for olverembatinib. The company has achieved commercial success in China with their third-generation BCR-ABL TKI for CML and demonstrates strong capabilities in developing differentiated targeted therapies. BIOSECURE risk appears low given their clear status, making them an attractive partner for US pharma seeking China-originated assets.
Structure: As a US-listed company (NASDAQ: AAPG), Ascentage likely operates through a Variable Interest Entity (VIE) structure typical of Chinese biotechs accessing US capital markets. The 20-F filing with SEC indicates standard VIE disclosures and corporate structure transparency expected for NASDAQ-listed entities.
Key People
| Name | Title | Education | Flags |
|---|---|---|---|
Dajun Yang 杨大俊 | Founder, Chairman & CEO | PhD, University of Michigan |
Ownership & Shareholder Structure
Corporate Events
Ascentage Pharma 20-F Annual Report
20-F annual report filed with SEC. Contains corporate structure, VIE disclosures, and risk factors.
Takeda partnership for olverembatinib
Takeda licensed global rights to olverembatinib for CML. Validates China-originated targeted therapy in competitive hematology space.
Clinical Trials(50 total)
7
Phase 3
2
Phase 2
8
Phase 1
3
Phase 1, Phase 2
| NCT ID | Interventions | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07178912 | Blinatumomab, olverembatinib | Ph.2 | NOT YET RECRUITING | 60 |
| NCT07428486 | Fludarabine, Cytarabine, G-CSF, Lisaftoclax, Pelcitoclax | Ph.1 | NOT YET RECRUITING | 24 |
| NCT07424833 | APG-3288 | Ph.1 | NOT YET RECRUITING | 180 |
| NCT06641414 | Lisaftoclax (APG-2575), Azacitidine Injection, Placebo | Ph.3 | RECRUITING | 490 |
| NCT06687070 | APG -2449, PLD | Ph.1 | RECRUITING | 50 |
| NCT06640361 | Olverembatinib | Ph.3 | RECRUITING | 40 |
| NCT06182969 | APG-2575, Placebo | Ph.1, Ph.2 | RECRUITING | 40 |
| NCT06389292 | APG-2575(Lisaftoclax ), Placebo, Azacitidine Injection | Ph.3 | RECRUITING | 486 |
| NCT06319456 | Lisaftoclax (APG-2575), Acalabrutinib, Fludarabine, Cyclophosphamide，CTX, Rituximab, Chlorambucil | Ph.3 | RECRUITING | 344 |
| NCT06423911 | olverembatinib, Bosutinib | Ph.3 | RECRUITING | 285 |
| NCT06104566 | lisaftoclax +BTK inhibitor, BTK inhibitor | Ph.3 | RECRUITING | 400 |
| NCT06051409 | Olverembatinib, Imatinib | Ph.3 | RECRUITING | 350 |
| NCT05773586 | APG-5918, Placebo | Ph.1 | RECRUITING | 105 |
| NCT05701306 | APG-115, APG-2575 | Ph.1 | RECRUITING | 100 |
| NCT05415098 | APG-5918 | Ph.1 | UNKNOWN | 90 |
| NCT05517616 | [14C ]APG-2575 | Ph.1 | COMPLETED | 6 |
| NCT05186012 | APG-1252, Chidamide | Ph.1, Ph.2 | RECRUITING | 51 |
| NCT04893759 | Pelcitoclax | Ph.1 | TERMINATED | 2 |
| NCT05147467 | APG2575 | Ph.2 | UNKNOWN | 75 |
| NCT04942067 | APG-2575+ Pd, APG-2575 + DRd | Ph.1, Ph.2 | UNKNOWN | 108 |
Showing 20 of 50 trials
Drug Molecules (ChEMBL)
OLVEREMBATINIB
Phase 3Top Publications (by citations)
Management of chronic myeloid leukemia in 2023 - common ground and common sense.
Senapati J, Sasaki K, Issa GC, Lipton JH, Radich JP, Jabbour E, Kantarjian HM.
Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring.
Jabbour E, Kantarjian H.
Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial.
Jiang Q, Li Z, Qin Y, Li W, Xu N, Liu B, Zhang Y, Meng L, Zhu H, Du X, Chen S, Liang Y, Hu Y, Liu X, Song Y, Men L, Chen Z, Niu Q, Wang H, Lu M, Yang D, Zhai Y, Huang X.
The BCL-2 inhibitor APG-2575 resets tumor-associated macrophages toward the M1 phenotype, promoting a favorable response to anti-PD-1 therapy via NLRP3 activation.
Luo F, Li H, Ma W, Cao J, Chen Q, Lu F, Qiu M, Zhou P, Xia Z, Zeng K, Zhan J, Zhou T, Luo Q, Pan W, Zhang L, Lin C, Huang Y, Zhang L, Yang D, Zhao H.
Olverembatinib: First Approval.
Dhillon S.
Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting.
Hou JZ, Ye JC, Pu JJ, Liu H, Ding W, Zheng H, Liu D.
Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results.
Cortes JE, Sasaki K, Kim DW, Hughes TP, Etienne G, Mauro MJ, Hochhaus A, Lang F, Heinrich MC, Breccia M, Deininger M, Goh YT, Janssen JJWM, Talpaz M, de Soria VGG, le Coutre P, DeAngelo DJ, Damon A, Cacciatore S, Polydoros F, Agrawal N, Rea D.
The cure of leukemia through the optimist's prism.
Kantarjian HM, Jain N, Garcia-Manero G, Welch MA, Ravandi F, Wierda WG, Jabbour EJ.
2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia.
Apperley JF, Milojkovic D, Cross NCP, Hjorth-Hansen H, Hochhaus A, Kantarjian H, Lipton JH, Malhotra H, Niederwieser D, Radich J, Rousselot P, Saussele S, Schiffer CA, Silver R, Soverini S, Stenke L, Turkina A, Casado LF, Castagnetti F, Cervantes F, Clark RE, Cortes J, Deininger M, Hughes TP, Janssen J, Jiang Q, Kim DW, Larson RA, Mahon FX, Mauro M, Mayer J, Nicolini FE, Pane F, Rea D, Richter J, Rosti G, Saglio G, Hehlmann R.
Adult Acute Lymphoblastic Leukemia: 2025 Update on Diagnosis, Therapy, and Monitoring.
Kantarjian H, Jabbour E.
BIOSECURE Risk
Company has clear BIOSECURE status and is not designated under BCC categories, indicating no current regulatory restrictions
Key Exposures:
- •VIE structure regulatory changes
- •China manufacturing dependencies
- •Cross-border data transfer requirements
Mitigation: NASDAQ listing suggests compliance with US regulatory standards and transparency requirements
BD Intelligence
Therapeutic Areas:
Recent Deals: Successfully out-licensed olverembatinib global rights to Takeda, demonstrating ability to execute international partnerships and validate China-originated assets in competitive oncology markets
Approach: Direct engagement with CEO Dajun Yang recommended given his founder status and deal execution track record. Focus on pipeline assets beyond olverembatinib and leverage their apoptosis expertise.
Red Flags
- ⚠Limited subsidiary transparency
- ⚠VIE structure regulatory uncertainties
- ⚠Dependence on China market for current commercial revenue
Quick Facts
- Key People
- 1
- Subsidiaries
- 0
- CDMO/CRO Subs
- 0
- Genomics Subs
- 0
- Direct BIOSECURE
- 0
- Corp Events
- 2
- Gov-Connected
- 0
- Clinical Trials
- 50
- Publications
- 10
- Drug Molecules
- 1
- Relationships
- 1
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (50 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (10 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: Company official filings, HKEX/SSE/SZSE disclosures
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.